The DOI matches its Crossref record; 276 of the 276 references it cites were found in a registry or an index.
Delivering safer immunotherapies for cancer
Open accessAbstract
Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects. Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches based in drug delivery technology to enhance the safety and potency of these treatments. These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma
McDermott, D. F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1872 · Cited by 63
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Grimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.6.1823 · Cited by 2,204
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 2×
“Preclinical studies in rats, non-human primates, and cultures of human cells failed to predict nearly lethal cytokine release syndrome in the six healthy volunteers first dosed with TeGenero's CD28SA TGN1412 [101].”
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Whole Body Irradiation—Radiobiology or Medicine?
Mole, R. H. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-305-234 · Cited by 1,123
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Sindrilaru, A., Peters, T., Wieschalka, S., Baican, C., Baican, A., Peter, H., Hainzl, A., Schatz, S., Qi, Y., Schlecht, A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44490 · Cited by 1,100
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Liao, W., Lin, J.-X., & Leonard, W. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.004 · Cited by 1,075
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Mechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Humanized mice for immune system investigation: progress, promise and challenges
Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., & Greiner, D. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3311 · Cited by 979
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Banaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 784
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles
Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A., & Irvine, D. J. (2010) · Nature Medicine · doi:10.1038/nm.2198 · Cited by 750
Self-citationBuilding better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A., & Swartz, M. A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.006 · Cited by 679
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
Trastuzumab containing regimens for early breast cancer
Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D'Amico, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006243.pub2 · Cited by 604
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Pober, J. S. (1988) · PubMed · Cited by 594
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Self-citationAtkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 583
Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing
Martino, M. M., Briquez, P. S., Güç, E., Tortelli, F., Kilarski, W. W., Metzger, S., Rice, J. J., Kuhn, G. A., Müller, R., Swartz, M. A., et al. (2014) · Science · doi:10.1126/science.1247663 · Cited by 498
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
Cancer Nanomedicine: From Drug Delivery to Imaging
Chow, E. K.-H., & Ho, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005872 · Cited by 491
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.292 · Cited by 485
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
Martino, M. M., Tortelli, F., Mochizuki, M., Traub, S., Ben-David, D., Kuhn, G. A., Müller, R., Livne, E., Eming, S. A., & Hubbell, J. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002614 · Cited by 459
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
Lu, M., Cohen, M. H., Rieves, D., & Pazdur, R. (2010) · American Journal of Hematology · doi:10.1002/ajh.21656 · Cited by 443
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Charych, D. H., Hoch, U., Langowski, J. L., Lee, S. R., Addepalli, M. K., Kirk, P. B., Sheng, D., Liu, X., Sims, P. W., VanderVeen, L. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1631 · Cited by 398
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
Self-citationKrieg, C., Létourneau, S., Pantaleo, G., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002569107 · Cited by 380
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Self-citationFourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Regnier, R. (1992) · PubMed · Cited by 362
Grimm, E. A., Robb, R. J., Roth, J. A., et al. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.4.1356 · Cited by 354
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 339
Li, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., & Natali, P. G. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.3.1139 · Cited by 335
Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., et al. (2003) · PubMed · Cited by 335
Galanis, E., Hartmann, L. C., Cliby, W. A., Long, H. J., Peethambaram, P. P., Barrette, B. A., Kaur, J. S., Haluska, P. J., Aderca, I., Zollman, P. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2762 · Cited by 317
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis
Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., & Zardi, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590507 · Cited by 316
Martino, M. M., & Hubbell, J. A. (2010) · The FASEB Journal · doi:10.1096/fj.09-151282 · Cited by 316
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
Huang, B., Abraham, W. D., Zheng, Y., Bustamante López, S. C., Luo, S. S., & Irvine, D. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5447 · Cited by 312
Self-citationDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
Nirschl, C. J., & Drake, C. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1972 · Cited by 306
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses
Seung, S. K., Curti, B. D., Crittenden, M., Walker, E., Coffey, T., Siebert, J. C., Miller, W., Payne, R., Glenn, L., Bageac, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003649 · Cited by 303
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300 · cited 3×
“but not humans, explaining the inadequacy of the non-human primate studies [110].”
InfluentialXu, Z., Wang, Y., Zhang, L., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn500216y · Cited by 284
Vascular leak syndrome: a side effect of immunotherapy
Baluna, R., & Vitetta, E. S. (1997) · Immunopharmacology · doi:10.1016/s0162-3109(97)00041-6 · Cited by 280
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 276
Sakamoto, N., Ishikawa, T., Kokura, S., Okayama, T., Oka, K., Ideno, M., Sakai, F., Kato, A., Tanabe, M., Enoki, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0632-8 · Cited by 270
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
Biot, C., Rentsch, C. A., Gsponer, J. R., Birkhäuser, F. D., Jusforgues-Saklani, H., Lemaître, F., Auriau, C., Bachmann, A., Bousso, P., Demangel, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003586 · Cited by 269
Enhancing cell therapies from the outside in: Cell surface engineering using synthetic nanomaterials
Stephan, M. T., & Irvine, D. J. (2011) · Nano Today · doi:10.1016/j.nantod.2011.04.001 · Cited by 266
Self-citationVidal, L., Gafter-Gvili, A., Leibovici, L., Dreyling, M., Ghielmini, M., Hsu Schmitz, S.-F., Cohen, A., & Shpilberg, O. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn478 · Cited by 266
Emerging Tim-3 functions in antimicrobial and tumor immunity
Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C., & Kuchroo, V. K. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.003 · Cited by 258
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Bartkowiak, T., & Curran, M. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00117 · Cited by 256
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Benne, N., van Duijn, J., Kuiper, J., Jiskoot, W., & Slütter, B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.033 · Cited by 248
Smith, B. R., Ghosn, E. E. B., Rallapalli, H., Prescher, J. A., Larson, T., Herzenberg, L. A., & Gambhir, S. S. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.62 · Cited by 237
Zhu, S., Niu, M., O’Mary, H., & Cui, Z. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400216r · Cited by 232
Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
Aznar, M. A., Tinari, N., Rullán, A. J., Sánchez-Paulete, A. R., Rodriguez-Ruiz, M. E., & Melero, I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601145 · Cited by 230
Managing toxicities of high-dose interleukin-2.
Schwartz, R. N., Stover, L. L., & Dutcher, J. P. (2002) · PubMed · Cited by 229
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
White, A. L., Chan, H. T. C., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al-Shamkhani, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101135 · Cited by 226
Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation
Li, S.-Y., Liu, Y., Xu, C.-F., Shen, S., Sun, R., Du, X.-J., Xia, J.-X., Zhu, Y.-H., & Wang, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.044 · Cited by 222
Cotran, R. S., Pober, J. S., Gimbrone, M. A., Springer, T. A., Wiebke, E. A., Gaspari, A. A., Rosenberg, S. A., & Lotze, M. T. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.6.1883 · Cited by 221
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Marabelle, A., Kohrt, H., Caux, C., & Levy, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2116 · Cited by 214
Pharmacokinetics of recombinant interleukin 2 in humans.
Konrad, M. W., Hemstreet, G. P., Hersh, E. M., Mansell, P. W. A., Mertelsmann, R. H., Kolitz, J. E., & Bradley, E. C. (1990) · PubMed · Cited by 214
Sato, K., Sato, N., Xu, B., Nakamura, Y., Nagaya, T., Choyke, P. L., Hasegawa, Y., & Kobayashi, H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6843 · Cited by 213
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., et al. (2012) · Blood · doi:10.1182/blood-2011-05-355222 · Cited by 210
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles
Stephan, M. T., Stephan, S. B., Bak, P., Chen, J., & Irvine, D. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.029 · Cited by 209
Self-citationLétourneau, S., van Leeuwen, E. M. M., Krieg, C., Martin, C., Pantaleo, G., Sprent, J., Surh, C. D., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909384107 · Cited by 205
Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3007 · Cited by 204
Fransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R., & Melief, C. J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0781 · Cited by 200
Kwong, B., Gai, S. A., Elkhader, J., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 197
Self-citationImmunological Principles Guiding the Rational Design of Particles for Vaccine Delivery
Gause, K. T., Wheatley, A. K., Cui, J., Yan, Y., Kent, S. J., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.6b07343 · Cited by 196
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194 · cited 2×
“densities promoting extensive cell-cell contacts as in lymphoid tissues [105].”
Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
Jeanbart, L., Ballester, M., de Titta, A., Corthésy, P., Romero, P., Hubbell, J. A., & Swartz, M. A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0019-t · Cited by 191
Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.65 · Cited by 191
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Chen, Y., Xia, R., Huang, Y., Zhao, W., Li, J., Zhang, X., Wang, P., Venkataramanan, R., Fan, J., Xie, W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13443 · Cited by 190
Bramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.16-1995 · Cited by 188
Surace, L., Lysenko, V., Fontana, A. O., Cecconi, V., Janssen, H., Bicvic, A., Okoniewski, M., Pruschy, M., Dummer, R., Neefjes, J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.009 · Cited by 179
Kwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 175
Self-citationBourquin, C., Anz, D., Zwiorek, K., Lanz, A.-L., Fuchs, S. P., Weigel, S., Wurzenberger, C., von der Borch, P., Golić, M., Moder, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.2990 · Cited by 174
Smirnov, D., Schmidt, J. J., Capecchi, J. T., & Wightman, P. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.061 · Cited by 174
Niu, L., Strahotin, S., Hewes, B., Zhang, B., Zhang, Y., Archer, D., Spencer, T., Dillehay, D., Kwon, B., Chen, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4194 · Cited by 171
Self-citationvan Mierlo, G. J. D., Boonman, Z. F. H. M., Dumortier, H. M. H., den Boer, A. T., Fransen, M. F., Nouta, J., van der Voort, E. I. H., Offringa, R., Toes, R. E. M., & Melief, C. J. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6753 · Cited by 171
Ilyinskii, P. O., Roy, C. J., O’Neil, C. P., Browning, E. A., Pittet, L. A., Altreuter, D. H., Alexis, F., Tonti, E., Shi, J., Basto, P. A., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.027 · Cited by 171
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Goebeler, M.-E., & Bargou, R. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2016.1161185 · Cited by 170
Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
Huang, Z., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.013 · Cited by 169
Borsi, L., Carnemolla, B., Nicolò, G., Spina, B., Tanara, G., & Zardi, L. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520504 · Cited by 168
Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation
Singh, M., Khong, H., Dai, Z., Huang, X.-F., Wargo, J. A., Cooper, Z. A., Vasilakos, J. P., Hwu, P., & Overwijk, W. W. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401160 · Cited by 166
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
Dotan, E., Aggarwal, C., & Smith, M. R. (2010) · PubMed Central · Cited by 166
Cochran, A. J., Morton, D. L., Stern, S., Lana, A. M. A., Essner, R., & Wen, D.-R. (2001) · Modern Pathology · doi:10.1038/modpathol.3880358 · Cited by 165
Tacke, M., Hanke, G., Hanke, T., & Hünig, T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270136 · Cited by 163
Huo, M., Zhao, Y., Satterlee, A., Wang, Y., Xu, Y., & Huang, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.013 · Cited by 159
Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting
Muthana, M., Kennerley, A. J., Hughes, R., Fagnano, E., Richardson, J., Paul, M., Murdoch, C., Wright, F., Payne, C., Lythgoe, M. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms9009 · Cited by 157
Chemical control of protein stability and function in living mice
Banaszynski, L. A., Sellmyer, M. A., Contag, C. H., Wandless, T. J., & Thorne, S. H. (2008) · Nature Medicine · doi:10.1038/nm.1754 · Cited by 155
Non-infectious pulmonary toxicity of rituximab: a systematic review
Hadjinicolaou, A. V., Nisar, M. K., Parfrey, H., Chilvers, E. R., & Östör, A. J. K. (2011) · Rheumatology · doi:10.1093/rheumatology/ker290 · Cited by 154
Heinzerling, L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J. G., Elzaouk, L., Pavlovic, J., & Moelling, K. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.35 · Cited by 154
Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00078 · Cited by 153
Self-citationSznol, M., Kluger, H. M., Callahan, M. K., Postow, M. A., Gordon, R. A., Segal, N. H., Rizvi, N. A., Lesokhin, A. M., Atkins, M. B., Kirkwood, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba9003 · Cited by 151
Cole, C., Qiao, J., Kottke, T. J., Díaz, R. M., Ahmed, A. U., Sanchez-Perez, L. A., Brunn, G. J., Thompson, J., Chester, J. D., & Vile, R. G. (2005) · Nature Medicine · doi:10.1038/nm1297 · Cited by 148
Macrophages in gene therapy: cellular delivery vehicles and in vivo targets
Burke, B., Sumner, S., Maitland, N. J., & Lewis, C. E. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.3.417 · Cited by 147
Lebbé, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., O'Day, S. J., Konto, C., Cykowski, L., McHenry, M. B., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu441 · Cited by 146
In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes
Zheng, Y., Stephan, M. T., Gai, S. A., Abraham, W. D., Shearer, A., & Irvine, D. J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.037 · Cited by 145
Self-citationImmunocytokines for cancer treatment: past, present and future
Neri, D., & Sondel, P. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.006 · Cited by 145
Egilmez, N. K., Jong, Y. S., Sabel, M. S., Jacob, J. S., Mathiowitz, E., & Bankert, R. B. (2000) · PubMed · Cited by 143
Palazón, A., Teijeira, Á., Martínez‐Forero, I., Hervás‐Stubbs, S., Roncal, C., Peñuelas, I., Dubrot, J., Morales‐Kastresana, A., Perez‐Gracia, J. L., Ochoa, M. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1733 · Cited by 143
Zwiorek, K., Bourquin, C., Battiany, J., Winter, G., Endres, S., Hartmann, G., & Coester, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9410-5 · Cited by 141
Hernandez-Chacon, J. A., Li, Y., Wu, R. C. H., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P., & Radvanyi, L. G. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209e7ec · Cited by 141
Qiao, J., Kottke, T. J., Willmon, C. L., Galivo, F., Wongthida, P., Díaz, R. M., Thompson, J., Ryno, P. K., Barber, G. N., Chester, J. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1681 · Cited by 141
Liu, H., Kwong, B., & Irvine, D. J. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101266 · Cited by 140
Self-citationNanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy
Chu, D., Zhao, Q., Yu, J., Zhang, F., Zhang, H., & Wang, Z. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201500998 · Cited by 139
SPION primes THP1 derived M2 macrophages towards M1-like macrophages
Laskar, A., Eilertsen, J., Li, W., & Yuan, X.-M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.115 · Cited by 138
4-1BB agonism: adding the accelerator to cancer immunotherapy
Chester, C., Ambulkar, S. S., & Kohrt, H. E. K. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1829-2 · Cited by 133
Kourtis, I. C., Hirosue, S., de Titta, A., Kontos, S., Stegmann, T., Hubbell, J. A., & Swartz, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061646 · Cited by 129
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1639-3 · Cited by 127
Hori, Y., Winans, A., & Irvine, D. J. (2008) · Acta Biomaterialia · doi:10.1016/j.actbio.2008.11.019 · Cited by 127
Self-citationAntigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Tzeng, A., Kwan, B. H., Opel, C. F., Navaratna, T. A., & Wittrup, K. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416159112 · Cited by 125
Human endothelial cell cultures: Phenotypic modulation by leukocyte interleukins
Montesano, R., Orci, L., & VASSALLI, P. (1985) · Journal of Cellular Physiology · doi:10.1002/jcp.1041220313 · Cited by 125
Onitilo, A. A., Engel, J. M., & Stankowski, R. V. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614529603 · Cited by 124
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Berezhnoy, A., Castro, I., Levay, A. K., Malek, T. R., & Gilboa, E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69856 · Cited by 123
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Breast cancer: Biology, biomarkers, and treatments
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106535 · Cited by 973
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Metadata
- Authors
- Milling, L., Zhang, Y., & Irvine, D. J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 114
- Pages
- 79-101
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2617871758
- Cited by
- 305
- References
- 276
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.